skip to main content
Idioma:
Resultados 1 2 3 4 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Moore, Kathleen N ; Bookman, Michael ; Sehouli, Jalid ; Miller, Austin ; Anderson, Charles ; Scambia, Giovanni ; Myers, Tashanna ; Taskiran, Cagatay ; Robison, Katina ; Mäenpää, Johanna ; Willmott, Lyndsay ; Colombo, Nicoletta ; Thomes-Pepin, Jessica ; Liontos, Michalis ; Gold, Michael A ; Garcia, Yolanda ; Sharma, Sudarshan K ; Darus, Christopher J ; Aghajanian, Carol ; Okamoto, Aikou ; Wu, Xiaohua ; Safin, Rustem ; Wu, Fan ; Molinero, Luciana ; Maiya, Vidya ; Khor, Victor K ; Lin, Yvonne G ; Pignata, Sandro

Journal of clinical oncology, 2021-06, Vol.39 (17), p.JCO2100306-1855 [Periódico revisado por pares]

United States: Wolters Kluwer Health

Texto completo disponível

Citações Citado por
2
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Walker, Joan L ; Brady, Mark F ; Wenzel, Lari ; Fleming, Gini F ; Huang, Helen Q ; DiSilvestro, Paul A ; Fujiwara, Keiichi ; Alberts, David S ; Zheng, Wenxin ; Tewari, Krishnansu S ; Cohn, David E ; Powell, Matthew A ; Van Le, Linda ; Davidson, Susan A ; Gray, Heidi J ; Rose, Peter G ; Aghajanian, Carol ; Myers, Tashanna ; Alvarez Secord, Angeles ; Rubin, Stephen C ; Mannel, Robert S

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1380-1390 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
3
Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study
Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study

Brooks, Sandra E ; Carter, Randy L ; Plaxe, Steven C ; Basen-Engquist, Karen M ; Rodriguez, Michael ; Kauderer, James ; Walker, Joan L ; Myers, Tashanna K.N ; Drake, Janet G ; Havrilesky, Laura J ; Van Le, Linda ; Landrum, Lisa M ; Brown, Carol L

Gynecologic oncology, 2015-07, Vol.138 (1), p.101-108 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis

Landrum, Lisa M ; Moore, Kathleen N ; Myers, Tashanna K.N ; Lanneau, Grainger S ; McMeekin, D. Scott ; Walker, Joan L ; Gold, Michael A

Gynecologic oncology, 2009-02, Vol.112 (2), p.337-341 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
5
Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

Moore, Kathleen N ; Reid, Monica S ; Fong, Daniel N ; Myers, Tashanna K.N ; Landrum, Lisa M ; Moxley, Katherine M ; Walker, Joan L ; McMeekin, D. Scott ; Mannel, Robert S

Gynecologic oncology, 2008-08, Vol.110 (2), p.133-139 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
6
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates
Material Type:
Artigo 		Adicionar ao Meu Espaço

Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates

Landrum, Lisa M ; Gold, Michael A ; Moore, Kathleen N ; Myers, Tashanna K.N ; McMeekin, D.S ; Walker, Joan L

Gynecologic oncology, 2008-02, Vol.108 (2), p.342-347 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
“FICA Refocused: Finding Insights to Care for All (Including the Non-Religious)” (VT107)
“FICA Refocused: Finding Insights to Care for All (Including the Non-Religious)” (VT107)
Material Type:
Artigo 		Adicionar ao Meu Espaço

“FICA Refocused: Finding Insights to Care for All (Including the Non-Religious)” (VT107)

Fitch, Christina ; Schmidt, Ute ; Fliegel, Daniel ; Dietzen, Diane ; Myers, Tashanna

Journal of pain and symptom management, 2022-05, Vol.63 (5), p.839-839 [Periódico revisado por pares]

Madison: Elsevier Inc

Texto completo disponível

Citações Citado por
8
GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

O'Malley, David M. ; Myers, Tashanna K. N. ; Zamagni, Claudio ; Diver, Elisabeth ; Lorusso, Domenica

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5622-TPS5622 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
9
Adjuvant Chemotherapy for the Oldest Old Ovarian Cancer Patients : Can We Anticipate Toxicity-related Treatment Failure in a Vulnerable Population?
Adjuvant Chemotherapy for the Oldest Old Ovarian Cancer Patients : Can We Anticipate Toxicity-related Treatment Failure in a Vulnerable Population?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant Chemotherapy for the Oldest Old Ovarian Cancer Patients : Can We Anticipate Toxicity-related Treatment Failure in a Vulnerable Population?

MOORE, Kathleen N ; FRANK, Summer G ; ALWARD, Erin K ; LANDRUM, Lisa M ; MYERS, Tashanna K ; WALKER, Joan L ; GOLD, Michael A ; MCMEEKIN, D. Scott ; VESELY, Sara K ; MANNEL, Robert S

Cancer, 2009-04, Vol.115 (7), p.1472-1480 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível

Citações Citado por
10
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

Moore, Kathleen N. ; Angelergues, Antoine ; Konecny, Gottfried E. ; Banerjee, Susana N. ; Pignata, Sandro ; Colombo, Nicoletta ; Moroney, John William ; Cosgrove, Casey ; Lee, Jung-Yun ; Roszak, Andrzej ; Breuer, Shani ; Tromp, Jacqueline Maria ; Bello-Roufai, Diana ; Gilbert, Lucy ; Miller, Rowan ; Myers, Tashanna K. N. ; Wang, Yuemei ; Berkenblit, Anna ; Lorusso, Domenica ; Van Gorp, Toon

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA5507-LBA5507 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (29)
  2. Revistas revisadas por pares (31)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (31)
  2. Anais de Congresso  (2)
  3. Outros  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2009  (3)
  2. 2009Até2012  (5)
  3. 2013Até2018  (2)
  4. 2019Até2021  (9)
  5. Após 2021  (16)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.